基本數據
| LEI | 549300KN62PPGHBVXB46 |
| CIK | 1077183 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeoGenomics, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2026 NEOGENOMICS, INC. |
|
| April 28, 2026 |
Exhibit 10.1 SPECIAL ADVISOR AGREEMENT This special advisor agreement (the “Agreement”), effective April 14, 2026 (“Effective Date”) by and between Jeffrey S. Sherman (“Advisor”), an individual whose address is [REDACTED] and NeoGenomics Laboratories, Inc., a Florida corporation with its principal office located at 9490 NeoGenomics Way, Fort Myers, FL 33912 together with its affiliates, including |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2026 NEOGENOMICS, INC. |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| April 28, 2026 |
Exhibit 99.1 NeoGenomics Reports First Quarter 2026 Results First quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million Fort Myers, Florida (April 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnost |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 6, 2026 |
a2026ars ANNUAL REPORT 2025 Statement from the Chair of the Board of Directors Dear NeoGenomics Shareholders: I am writing to you today with enthusiasm as we wrap up what the Board considers to be a very successful 2025 at NeoGenomics. |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 17, 2026 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2025 Results Full year revenue increased 10% to $727 million; Full year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation Fort Myers, Florida, (February 17, 2026) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions tha |
|
| February 17, 2026 |
SUBSIDIARIES OF NEOGENOMICS, INC. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Inivata Limited, a UK limited company NeoGenomics Bioinformatics, Inc., a Florida corporation NeoGenomics Laboratories, Inc., a Florida corporation Suzhou NeoGenomics Pharmaceutical Research Co., Limited, a Suzhou, China corporation Trapelo Health, LLC, a Delaware limited liability company |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 17, 2026 NEOGENOMICS, INC. |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 17, 2026 |
NEOGENOMICS, INC. INSIDER TRADING POLICY Exhibit 19.1 NEOGENOMICS, INC. INSIDER TRADING POLICY Revised February 12, 2025 A. INTRODUCTION NeoGenomics, Inc. (the “Company”) recognizes that its directors, officers, and other employees may invest from time to time in the common stock of the Company. The Company’s Board of Directors (the “Board”) adopted this policy to promote compliance with applicable securities laws that prohibit persons w |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2026 NEOGENOMICS, INC. |
|
| January 12, 2026 |
Exhibit 99.1 NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – FT. MYERS, Fla., January 12, 2026—NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that ena |
|
| December 30, 2025 |
Exhibit 99.1 NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors FORT MYERS, Fla., December 30, 2025—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Direc |
|
| December 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2025 NEOGENOMICS, INC. |
|
| October 28, 2025 |
Exhibit 99.1 NeoGenomics Reports Third Quarter 2025 Results Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA Fort Myers, Florida (October 28, 2025) - NeoGen |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2025 NEOGENOMICS, INC. |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 NEOGENOMICS, INC. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| July 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2025 NEOGENOMICS, INC. |
|
| July 29, 2025 |
Exhibit 99.1 NeoGenomics Reports Second Quarter 2025 Results Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance Fort Myers, Florida (July 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quar |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2025 NEOGENOMICS, INC. |
|
| June 24, 2025 |
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors Exhibit 99.1 NeoGenomics Appoints Dr. Marjorie Green to Board of Directors FORT MYERS, Fla., June 24, 2025—NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No. |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 NEOGENOMICS, INC. |
|
| April 29, 2025 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Alicia Olivo (the “Executive”) and is effective as of January 1, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement b |
|
| April 29, 2025 |
, 2025, between NeoGenomics Inc. and Melody Harris Exhibit 10.6 Dear Melody: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end, effective as of June 1, 2025, (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your separation from employment and to outline your continuing obligations to the Company, including the restrictive covenants con |
|
| April 29, 2025 |
NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million Exhibit 99.1 NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compar |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| April 29, 2025 |
Employment Agreement, executed August 10, 2022, by and between NeoGenomics, Inc. and Alicia Olivo Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of August 10, 2022 by and between NeoGenomics, Inc. (the “Company”) and Alicia Olivo (the “Executive”). WHEREAS, the Executive and the Company entered into a certain letter agreement dated May 11, 2022 (the “Previous Letter Agreement”) memorializing the terms and conditions |
|
| April 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2025 NEOGENOMICS, INC. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 8, 2025 |
Amendment to the Amended and Restated Bylaws of NeoGenomics, Inc. AMENDMENT TO AMENDED AND RESTATED BYLAWS OF NEOGENOMICS, INC., a Nevada corporation April 4, 2025 The Amended and Restated Bylaws of NeoGenomics, Inc. are amended by inserting the following as Section 1.11. Section 1.11. Nominations for Directors. (a)Nominations for the election of directors may be made by the Board or by any Nominating Person (as defined herein) who (i) is entitled to vote for th |
|
| April 8, 2025 |
ANNUAL REPORT 2024 Corporate Officers Tony Zook Chief Executive Officer Beth Eastland Senior Vice President, Enterprise Sales Hutan Hashemi Chief Compliance Officer Andrew Lukowiak Chief Innovation Officer Nate Montgomery, MD, PhD Vice President, Medical Services and Medical Director, Durham, North Carolina Ali Olivo Executive Vice President, General Counsel and Business Development Gary Passman C |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2025 NEOGENOMICS, INC. |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 31, 2025 |
Employment Agreement effective April 1, 2025, by and between NeoGenomics, Inc. and Anthony Zook. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 1, 2025, by and between NeoGenomics, Inc. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2025 NEOGENOMICS, INC. |
|
| March 19, 2025 |
March 18, 2025 NeoGenomics Appoints Warren Stone as President & Chief Operating Officer Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2025 NEOGENOMICS, INC. |
|
| March 18, 2025 |
March 18, 2025 NeoGenomics Appoints Warren Stone as President & Chief Operating Officer Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2025 NEOGENOMICS, INC. |
|
| February 18, 2025 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Inivata Limited, a UK limited company NeoGenomics Bioinformatics, Inc., a Florida corporation NeoGenomics Europe, SA, a Swiss société anonyme NeoGenomics Laboratories, Inc., a Florida corporation NeoGenomics Singapore, Pte. Ltd., a Singapore private limited company Suzhou NeoGenomics Pharmaceutical Research Co., Limited, a Suzhou, China corporation Tr |
|
| February 18, 2025 |
NeoGenomics, Inc. Insider Trading Policy Exhibit 19.1 NEOGENOMICS, INC. INSIDER TRADING POLICY Revised February 12, 2025 A. INTRODUCTION NeoGenomics, Inc. (the “Company”) recognizes that its directors, officers, and other employees may invest from time to time in the common stock of the Company. The Company’s Board of Directors (the “Board”) adopted this policy to promote compliance with applicable securities laws that prohibit persons w |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 18, 2025 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2024 Results Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth Fort Myers, Florida, (February 18, 2025) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended Dece |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 NEOGENOMICS, INC. |
|
| January 15, 2025 |
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - Long-Range Plan reflects 12-13% revenue growth annually - Presentation and webcast at 43rd Annual J. |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2025 NEOGENOMICS, INC. |
|
| January 10, 2025 |
NeoGenomics Announces Chief Executive Officer Succession Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance FT. |
|
| January 10, 2025 |
Letter Agreement between NeoGenomics, Inc. and Christopher Smith, dated January 8, 2025 Exhibit 10.1 January 8, 2025 Christopher Smith Dear Chris: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end as a result of your retirement, effective as of April 1, 2025 (the “Retirement Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in |
|
| January 10, 2025 |
Special Advisor Agreement between NeoGenomics, Inc. and Christopher Smith, effective April 1, 2025. Exhibit 10.2 Special Advisor Agreement This special advisor agreement (the “Agreement”), effective April 1, 2025 (“Effective Date”) by and between Christopher Smith (“Advisor”), an individual whose address is 17409 Via Lugano Court, Miramar Lakes, Florida 33913 and NeoGenomics Laboratories, Inc., a Florida corporation with its principal office located at 9490 NeoGenomics Way, Fort Myers, FL 33912 |
|
| November 14, 2024 |
NEO / NeoGenomics, Inc. / T. Rowe Price Investment Management, Inc. Passive Investment SC 13G/A 1 neo13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NEOGENOMICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64049M209 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuan |
|
| November 14, 2024 |
NEO / NeoGenomics, Inc. / JANUS HENDERSON GROUP PLC - JANUS NEW Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: NEOGENOMICS INC Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [ |
|
| November 5, 2024 |
Exhibit 99.1 NeoGenomics Reports Third Quarter 2024 Results Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million Fort Myers, Florida (November 5, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2024 NEOGENOMICS, INC. |
|
| November 5, 2024 |
NeoGenomics, Inc. Code of Business Conduct and Ethics Exhibit 14.1 NeoGenomics Code of Business Conduct and Ethics Living Our Values Table of Contents INTRODUCTION 2 DECISION MAKING USING THE CODE 2 OUR RESPONSIBILITIES UNDER THE CODE 2 OUR VALUES 3 OUR RELATIONSHIPS WITH COLLEAGUES 3 OUR RELATIONSHIP WITH CUSTOMERS AND BUSINESS PARTNERS 4 OUR OBLIGATIONS TO THE COMPANY 5 OUR FINANCIAL OPERATIONS AND RESPONSIBILITIES 7 OUR RELATIONSHIP WITH THE REGUL |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| July 29, 2024 |
Exhibit 99.1 NeoGenomics Reports Second Quarter 2024 Results Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million Fort Myers, Florida (July 29, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended Ju |
|
| July 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2024 NEOGENOMICS, INC. |
|
| June 13, 2024 |
As filed with the Securities and Exchange Commission on June 13, 2024 As filed with the Securities and Exchange Commission on June 13, 2024 Registration No. |
|
| June 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2024 NEOGENOMICS, INC. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| April 30, 2024 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Second Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”) and is effective as of April 29, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the E |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 NEOGENOMICS, INC. |
|
| April 30, 2024 |
NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights •Consolidated revenue increased |
|
| April 30, 2024 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Warren Stone (the “Executive”) and is effective as of April 29, 2024 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement by |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2024 NEOGENOMICS, INC. |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 8, 2024 |
2023 ANNUAL REPORT Serving patients. Saving lives. neogenomics.comStatement from the Chair of the Board of Directors Dear NeoGenomics Shareholders – I would like to express the Board’s appreciation for your continued support and trust in our mission to save lives by improving patient care. Your commitment has been foundational in propelling our company forward. 2023 was a strong year of execution |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 26, 2024 |
Form of PSU Agreement under the NeoGenomics, Inc. 2023 Equity Incentive Plan. NOTICE OF GRANT OF PSU AWARD NeoGenomics, Inc. 2023 Equity Incentive Plan FOR GOOD AND VALUABLE CONSIDERATION, NeoGenomics, Inc. (the “Company”) hereby grants, pursuant to the provisions of the NeoGenomics, Inc. 2023 Equity Incentive Plan (the “Plan”), to the Grantee designated in this Notice of Grant of PSU Award (the “Notice”), the number of performance-based RSUs (“PSUs”) set forth in this Noti |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2024 NEOGENOMICS, INC. |
|
| February 23, 2024 |
Form of PSU Agreement under the NeoGenomics, Inc. 2023 Equity Incentive Plan NOTICE OF GRANT OF PSU AWARD NeoGenomics, Inc. 2023 Equity Incentive Plan FOR GOOD AND VALUABLE CONSIDERATION, NeoGenomics, Inc. (the “Company”) hereby grants, pursuant to the provisions of the NeoGenomics, Inc. 2023 Equity Incentive Plan (the “Plan”), to the Grantee designated in this Notice of Grant of PSU Award (the “Notice”), the number of performance-based RSUs (“PSUs”) set forth in this Noti |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2024 NEOGENOMICS, INC. |
|
| February 20, 2024 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, a UK limited company Inivata, Inc., a Delaware corporation Minuet Diagnostics, Inc., a Delaware corpor |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 20, 2024 |
Executive Officer Compensation Clawback Policy EXHIBIT 97.1 NEOGENOMICS, INC. NASDAQ RULE 5608 EXECUTIVE OFFICER COMPENSATION CLAWBACK POLICY EFFECTIVE December 1, 2023 1.Policy Purpose. The purpose of this NeoGenomics, Inc. Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy (this “Policy”) is to enable NeoGenomics, Inc. and its subsidiaries and affiliates (the “Company”) to recover Erroneously Awarded Compensation in the event th |
|
| February 20, 2024 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 res |
|
| February 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 20, 2024 NEOGENOMICS, INC. |
|
| February 14, 2024 |
NEO / NeoGenomics, Inc. / T. Rowe Price Investment Management, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NEOGENOMICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64049M209 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fi |
|
| February 13, 2024 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: NeoGenomics Inc Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 9, 2024 |
NEO / NeoGenomics, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INC Passive Investment SC 13G/A 1 neoa120924.htm BROWN ADVISORY INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeoGenomics, Inc. (Name of Issuer) (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 22, 2024 |
NEO / NeoGenomics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us64049m2098012224.txt us64049m2098012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) NEOGENOMICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64049M209 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 6, 2023 |
NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Exhibit 99.1 NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022. Third Quarter 2023 Highlights Q3 202 |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 NEOGENOMICS, INC. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 8, 2023 |
NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Exhibit 99.1 NeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022. Highlights •Consolidated revenue increased 18 |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2023 NEOGENOMICS, INC. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2023 NEOGENOMICS, INC. |
|
| June 29, 2023 |
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors Exhibit 99.1 NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new indep |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 S-8 1 s-8june2023.htm S-8 As filed with the Securities and Exchange Commission on June 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeoGenomics, Inc. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organi |
|
| June 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 NEOGENOMICS, INC. |
|
| May 17, 2023 |
Form of PSU Agreement under the NeoGenomics, Inc. Amended and Restated Equity Incentive Plan. Exhibit 10.1 PERFORMANCE STOCK UNIT AWARD AGREEMENT NEOGENOMICS, INC. AMENDED AND RESTATED EQUITY INCENTIVE PLAN NeoGenomics, Inc. (the “Company”) grants to the Grantee named below (“you”) the number of performance stock units (“PSUs”) set forth below (the “Award”) under the Company’s Amended and Restated Equity Incentive Plan (the “Plan”). The PSUs shall be considered RSUs for purposes of the Pla |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 NEOGENOMICS, INC. |
|
| May 17, 2023 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”) and is effective as of May 12, 2023 (the “Effective Date”). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreement by |
|
| May 9, 2023 |
Offer Letter dated March 27, 2023 between NeoGenomics Laboratories and Greg Aunan. exhibit101-offerletterda |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 NEOGENOMICS, INC. |
|
| May 8, 2023 |
NeoGenomics Reports First Quarter 2023 Results First Quarter Revenue Increased 17% to $137 Million Exhibit 99.1 NeoGenomics Reports First Quarter 2023 Results First Quarter Revenue Increased 17% to $137 Million Fort Myers, Florida (May 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023. Highlights •C |
|
| April 7, 2023 |
Transforming Cancer Care for Patients and Providers 2022 ANNUAL REPORT[THISPAGEINTENTIONALLYLEFTBLANK]NeoGenomics Laboratories — 1 Statement from the Chair of the Board of Directors: 2022 was a year of significant change and operational challenges for NeoGenomics. |
|
| April 7, 2023 |
Table of Contents UNITE D STATE S SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 7, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) |
|
| April 4, 2023 |
neoinvestordaymasterxsl Safe Harbor Disclosure This presentation has been prepared by NeoGenomics, Inc. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2023 NEOGENOMICS, INC. |
|
| February 24, 2023 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, UK Limited Company Inivata, Inc., Delaware Corporation Minuet Diagnostics, Inc., a Delaware corporatio |
|
| February 24, 2023 |
Employment Agreement, dated November 2, 2022 by and between NeoGenomics, Inc. and Warren Stone Exhibit 10.18 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of November 2, 2022 by and between NeoGenomics, Inc. (the “Company”) and Warren Stone (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company desir |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 24, 2023 |
Exhibit 10.23 December 20, 2022 William Bonello Dear Bill: As we have discussed, your employment with NeoGenomics, Inc. (the “Company”) is coming to an end, effective as of December 31, 2022, (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in this Agreement will have t |
|
| February 24, 2023 |
Employment Agreement, dated November 14, 2022, by and between NeoGenomics, Inc. and Melody Harris Exhibit 10.19 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of November 14, 2022 by and between NeoGenomics, Inc. (the “Company”) and Melody Harris (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company des |
|
| February 23, 2023 |
Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2022 Results Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million Fort Myers, Florida, (February 23, 2023) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2022 resu |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2023 NEOGENOMICS, INC. |
|
| February 10, 2023 |
NEO / NeoGenomics, Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. |
|
| February 9, 2023 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| February 9, 2023 |
NEO / NeoGenomics, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NeoGenomics, Inc. (Name of Issuer) (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) |
|
| February 6, 2023 |
NEO / NeoGenomics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NEOGENOMICS, INC (Name of Issuer) Common Stock (Title of Class of Securities) 64049M209 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| January 23, 2023 |
NEO / NeoGenomics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us64049m2098012323.txt us64049m2098012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) NEOGENOMICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64049M209 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2023 NEOGENOMICS, INC. |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2022 NEOGENOMICS, INC. |
|
| December 6, 2022 |
Exhibit 99.1 NeoGenomics Announces Chief Financial Officer Transition Jeffrey S. Sherman Appointed Chief Financial Officer FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that Jeffrey S. Sherman will join the company as Chief Financial Officer, effective December 7, 2022. M |
|
| December 6, 2022 |
Employment Agreement of Jeffrey S. Sherman, dated December 5, 2022 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2022 by and between NeoGenomics, Inc. (the “Company”) and Jeffrey S. Sherman (the “Executive”). WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; and WHEREAS, the Company desires |
|
| December 5, 2022 |
Exhibit 99.2 NEOGENOMICS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Jeff Sherman (the ?Participant?) as of December 5, 2022. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant a Non-Qualified Stock Option to purchase sha |
|
| December 5, 2022 |
As filed with the Securities and Exchange Commission on December 5, 2022 As filed with the Securities and Exchange Commission on December 5, 2022 Registration No. |
|
| December 5, 2022 |
Exhibit 99.1 NEOGENOMICS, INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Jeff Sherman (the ?Participant?) as of December 5, 2022. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant shares of the Company?s Common Stock |
|
| December 5, 2022 |
EX-FILING FEES 2 exhibit107filingfeedecembe.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price per Share (3) Maximum Aggregate Offering Price Fe |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2022 NEOGENOMICS, INC. |
|
| November 8, 2022 |
Retention Agreement, dated October 15, 2022, by and between NeoGenomics, Inc. and Cynthia Dieter Exhibit 10.1 October 19, 2022 Cindy Dieter Dear Cindy, To incentivize you to remain with and committed to the success of the Company, we are pleased to offer you a special retention bonus (the ?Retention Bonus?), subject to the terms and conditions of this letter. You will be eligible to receive a cash bonus in a total amount equal to $150,000 (less applicable withholdings and deductions). The bon |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 8, 2022 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered into by and between NeoGenomics, Inc. (the ?Company?) and Christopher Smith (the ?Executive?) and is effective as of August 15, 2022 (the ?Effective Date?). Capitalized terms not defined in this Amendment have the respective meanings ascribed to them in the Employment Agreem |
|
| November 8, 2022 |
NeoGenomics Reports Third Quarter 2022 Results Third Quarter Revenue Increased 6% to $129 Million Exhibit 99.1 NeoGenomics Reports Third Quarter 2022 Results Third Quarter Revenue Increased 6% to $129 Million Fort Myers, Florida (November 8, 2022) - NeoGenomics, Inc. (NASDAQ: NEO) (the ?Company?), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its third-quarter results for the period ended September 30, 2022. Highl |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2022 NEOGENOMICS, INC. |
|
| November 7, 2022 |
Exhibit 99.1 NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors FT. MYERS, FL, NOVEMBER 7, 2022 ? NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez ? a veteran leader in medical devices and health care services ? to serve on its Board of Directors, effective |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2022 NEOGENOMICS, INC. |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2022 NEOGENOMICS, INC. |
|
| August 12, 2022 |
As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No. |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2022 NEOGENOMICS, INC. |
|
| August 12, 2022 |
Exhibit 99.2 NEOGENOMICS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Christopher Smith (the ?Participant?) as of [DATE]. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant a Non-Qualified Stock Option to purchase shares o |
|
| August 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| August 12, 2022 |
Exhibit 99.1 NEOGENOMICS, INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this ?Agreement?) is by and between NeoGenomics, Inc., a Nevada corporation (the ?Company?) and Christopher Smith (the ?Participant?) as of [DATE]. WHEREAS, to provide an incentive to Participant to focus on long-term Company performance, the Company desires to grant shares of the Company?s Common Stock to P |
|
| August 9, 2022 |
NeoGenomics Reports Revenue of $125 Million in the Second Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $125 Million in the Second Quarter Second-Quarter 2022 Results and Highlights ?Consolidated revenue increased 3% to $125 million ?Clinical Services revenue increased 4% to $106 million ?Pharma Services revenue decreased 4% to $19 million ?Chris Smith appointed CEO effective August 15, 2022 Fort Myers, Florida (August 9, 2022) - NeoGenomics, Inc. (NASDAQ: |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2022 NEOGENOMICS, INC. |
|
| July 21, 2022 |
Exhibit 99.1 NeoGenomics Announces Chief Executive Officer Appointment Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board Ft. Myers, Florida ? July 21, 2022 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing and global contract research services, today announced that industry veteran Chris Smith has bee |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2022 NEOGENOMICS, INC. |
|
| July 21, 2022 |
Employment Agreement, executed July 20, 2022, by and between NeoGenomics, Inc. and Christopher Smith Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of August 15, 2022 by and between NeoGenomics, Inc. (the ?Company?) and Christopher Smith (the ?Executive?). WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; and WHEREAS, the Company desires t |
|
| July 18, 2022 |
Exhibit 10.1 WITHOUT PREJUDICE/SUBJECT TO CONTRACT DATED July 11, 2022 INIVATA LIMITED (1) and CLIVE MORRIS (2) SETTLEMENT AGREEMENT 1 PARTIES: (1)Inivata Limited, a company incorporated in England & Wales, whose registered office is at The Glenn Berge Building, Babraham, Cambridge, England, CB22 3FH (the "Employer"); and (2)Clive Morris of [***] ("you"). BACKGROUND: (A)You are employed by the Emp |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 NEOGENOMICS, INC. |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 1 s-8june2022.htm S-8 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organi |
|
| June 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeoGenomics, Inc. |
|
| May 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 NEOGENOMICS, INC. |
|
| May 16, 2022 |
NeoGenomics Appoints Lynn Tetrault Interim CEO Exhibit 99.1 NeoGenomics Appoints Lynn Tetrault Interim CEO Ft. Myers, Florida ? May 16, 2022 - NeoGenomics, Inc. (NASDAQ: NEO) (the ?Company?), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim |
|
| May 11, 2022 |
Exhibit 99.1 NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary Ft. Myers, Florida ? May 9, 2022 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chie |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 NEOGENOMICS, INC. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 9, 2022 |
Exhibit 10.2 April 25, 2022 Lynn Tetrault [***] Dear Lynn, This letter agreement (this ?Agreement?) confirms the terms and conditions of your role as Executive Chair and Principal Executive Officer of NeoGenomics, Inc. (the ?Company?), effective as of April 19, 2022 (except as otherwise provided herein). At such time as a new Chief Executive Officer of the Company commences employment with the Com |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2022 NEOGENOMICS, INC. |
|
| April 27, 2022 |
NeoGenomics Reports Revenue of $117 Million in the First Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $117 Million in the First Quarter First-Quarter 2022 Results ?Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% ?Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services revenue increased 4% ?Pharma Services revenue |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 NEOGENOMICS, INC. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2022 NEOGENOMICS, INC. |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2022 NEOGENOMICS, INC. |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14 |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 14, 2022 |
NeoGenomics Laboratories ? II Transforming Patient Care 2021 ANNUAL REPORT I ? NeoGenomics Laboratories NeoGenomics Laboratories is a speciali d oncolo eference laboratory providing the latest technologies, testing, partnership opportunities, and interactive education to o logy and pathology communities. |
|
| March 28, 2022 |
Exhibit 99.1 NeoGenomics Announces CEO Departure and Initiates CEO Search Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance Ft. Myers, Florida?March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the ?Company?), a leading provider of cancer-focused genetic testing services and global oncology contract research serv |
|
| March 28, 2022 |
Separation Agreement, dated as of March 28, 2022, by and between NeoGenomics, Inc. and Mark Mallon Exhibit 10.1 March 28, 2022 Mark Mallon Dear Mark: As we have discussed, your employment with NeoGenomics, Inc. (the ?Company?) is coming to an end, effective as of March 28, 2022 (the ?Separation Date?). The purpose of this letter agreement (this ?Agreement?) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in this Agreement will have the respectiv |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2022 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-35756 74-2897368 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2022 NEOGENOMICS, INC. |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 25, 2022 |
Form of Executive Employment Agreement between NeoGenomics, Inc. and each of its executive officers Exhibit 10.11 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of [?] by and between NeoGenomics, Inc. (the ?Company?) and [?] (the ?Executive?). WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company; and WHEREAS, the Company desires to [continue to]1 e |
|
| February 25, 2022 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. Clarient Diagnostic Services, Inc., a Delaware corporation Clarient, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Inivata Limited, UK Limited Company Inivata, Inc., Delaware Corporation Minuet Diagnostics, Inc., a Delaware corporatio |
|
| February 23, 2022 |
Exhibit 99.1 NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021 Recent Highlights: ?Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% ?Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue in |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2022 NEOGENOMICS, INC. |
|
| February 10, 2022 |
NEO / NeoGenomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Ru |
|
| February 4, 2022 |
SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. |
|
| February 4, 2022 |
NEO / NeoGenomics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEOGENOMICS, INC (Name of Issuer) Common Stock (Title of Class of Securities) 64049M209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 27, 2022 |
NEO / NeoGenomics, Inc. / BlackRock Inc. Passive Investment us64049m2098012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) NEOGENOMICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64049M209 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 26, 2022 |
NEO / NeoGenomics, Inc. / BlackRock Inc. Passive Investment us64049m2098012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NEOGENOMICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64049M209 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2022 NEOGENOMICS, INC. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 NEOGENOMICS, INC. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. ( |
|
| November 4, 2021 |
Employment Agreement between NeoGenomics, Inc. and Halley Gilbert dated August 9, 2021. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 9th day of August, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and Halley Gilbert (?Executive?), an individual |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 NEOGENOMICS, INC. |
|
| November 4, 2021 |
NeoGenomics Reports Revenue of $121 Million in the Third Quarter Exhibit 99.1 NeoGenomics Reports Revenue of $121 Million in the Third Quarter Third-Quarter 2021 Results and Highlights: ?Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million ?Consolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consolidated revenue increased 12% when excludin |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2021 NEOGENOMICS, INC. |
|
| October 12, 2021 |
EX-99.1 2 a99-1pressrelease.htm EX-99.1 Exhibit 99.1 NeoGenomics Announces Board of Directors’ Transition Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year Ft. Myers, Florida – October 12, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer |
|
| September 1, 2021 |
As filed with the Securities and Exchange Commission on September 1, 2021 As filed with the Securities and Exchange Commission on September 1, 2021 Registration No. |
|
| September 1, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| September 1, 2021 |
Exhibit 99.1 INIVATA LIMITED Consolidated financial statements for the years ended 31 December 2020 and 2019 Registered number: 09144647 INIVATA LIMITED Consolidated financial statements for the years ended 31 December 2020 and 2019 Registered number: 09144647 Page(s) Report of Independent Auditors 3 Consolidated statements of comprehensive income 4 Consolidated balance sheets 5 Consolidated state |
|
| September 1, 2021 |
NEOGENOMICS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 NEOGENOMICS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On May 4, 2021, NeoGenomics Laboratories, Inc. (?NeoGenomics Laboratories?), a subsidiary of NeoGenomics, Inc. (?NeoGenomics? or the ?Company?), entered into a Share Purchase Agreement, by and between NeoGenomics Laboratories and Inivata Limited, a private limited company incorporated in England and Wal |
|
| August 10, 2021 |
NeoGenomics Investor Presentation August 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or juris |
|
| August 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 NEOGENOMICS, INC. |
|
| August 9, 2021 |
Employment Agreement between NeoGenomics, Inc. and Gina Wallar dated July 5, 2021. Exhibit 10.6 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 5th day of July, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #9, Fort Myers, Florida 33913 and Gina Wallar (?Executive?), an individual who r |
|
| August 9, 2021 |
Employment Agreement between NeoGenomics, Inc. and George Cardoza dated July 5, 2021. Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 5th day of July, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and George Cardoza (?Executive?), an individual wh |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact |
|
| August 9, 2021 |
Services Agreement between Inivata Limited and Clive Morris dated June 18, 2021. Exhibit 10.4 CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DATED 2021 INIVATA LIMITED (1) and CLIVE MORRIS (2) SERVICE AGREEMENT THIS AGREEMENT IS DATED 2021 PARTIES: (1)Inivata Limited whose registered office is at The Glenn Berge Building, Babraham, Camb |
|
| August 6, 2021 |
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter Exhibit 99.1 NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter Second-Quarter 2021 Results and Highlights: ?Consolidated revenue increased 40% to $122 million ?Clinical Services revenue increased 37% to $101 million ?Pharma Services revenue increased 55% to $20 million ?Completed the acquisitions of Trapelo Health in April and Inivata Limited in June Fort Myers, Florida |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 NEOGENOMICS, INC. |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 5, 2021 NEOGENOMICS, INC. |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2021 NEOGENOMICS, INC. |
|
| June 24, 2021 |
Exhibit 99.1 NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market Ft. Myers, Florida ? June 18, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and glob |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2021 NEOGENOMICS, INC. |
|
| June 2, 2021 |
As filed with the Securities and Exchange Commission on June 2, 2021 As filed with the Securities and Exchange Commission on June 2, 2021 Registration No. |
|
| June 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2021 NEOGENOMICS, INC. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac |
|
| May 6, 2021 |
NeoGenomics Investor Presentation May 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdic |
|
| May 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter Exhibit 99.1 NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter First-Quarter 2021 Results and Highlights: ?Consolidated revenue increased 9% to $116 million ?Clinical Services revenue increased 4% to $96 million ?Pharma Services revenue increased 46% to $19 million ?Completed the acquisition of Trapelo Health in April Fort Myers, Florida (May 5, 2021) - NeoGenomics, Inc. ( |
|
| May 5, 2021 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of May 4, 2021 by and among NeoGenomics, Inc., a Nevada corporation (the ?Company?), and the several Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are execu |
|
| May 5, 2021 |
Exhibit 99.1 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market ?NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million ?Completes $200 million strategic financing with leading oncol |
|
| May 5, 2021 |
Exhibit 99.1 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform ?Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market ?NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million ?Completes $200 million strategic financing with leading oncol |
|
| May 5, 2021 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of May 4, 2021 by and among NeoGenomics, Inc., a Nevada corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 4, 2021 (the ?Purchase Agreement?). Capi |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2021 NEOGENOMICS, INC. |
|
| May 5, 2021 |
Exhibit 2.1 Execution Version ? Exercise Notice Dated May 4, 2021 between THE INITIAL SELLERS and NEOGENOMICS LABORATORIES, INC. as Buyer and INIVATA LIMITED as the Company SHARE PURCHASE AGREEMENT RELATING TO THE SALE AND PURCHASE OF THE ENTIRE ISSUED SHARE CAPITAL OF INIVATA LIMITED TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATIONS 2 2. SALE OF SHARES 2 3. CONSIDERATION 2 4. ALLOCATION S |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14 |
|
| April 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2021 NEOGENOMICS, INC. |
|
| April 15, 2021 |
2020 | Exhibit 99.1 Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world?s leading cancer testing and information company. OUR VALUES Quality, Integrity, Accountability, Teamwork, and Innovation Becoming the World?s Leading |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e) |
|
| April 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2021 NEOGENOMICS, INC. |
|
| April 7, 2021 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-231608 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.001 per share 597,712 $49.375 $29,512,030 $3,220 (1) Pursuant to Rule 416(a) u |
|
| March 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2021 NEOGENOMICS, INC. |
|
| March 24, 2021 |
NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Exhibit 99.1 NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Ft. Myers, Florida ? March 24, 2021 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Intervention Insights, Inc. d/b/a Trapelo Health, an Informa |
|
| March 1, 2021 |
Employment Agreement between NeoGenomics, Inc. and Mark Mallon dated February 23, 2021 Exhibit 10.1 Execution Copy EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?) is made this 23rd day of February, 2021 by and between NeoGenomics, Inc. a Nevada corporation (?NeoGenomics? and collectively with any entity that is wholly or partially owned by NeoGenomics, the ?Company?), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and Mark Mallon (?Executive?), |
|
| March 1, 2021 |
NeoGenomics Announces CEO Succession Mark Mallon named CEO effective April 2021; Douglas M. |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2021 NEOGENOMICS, INC. |
|
| February 25, 2021 |
NeoGenomics Investor Presentation January 2021 1 Exhibit 99.1 Forward-Looking Statements 2 This presentation has been prepared by NeoGenomics, Inc. (?we,? ?us,? ?our,? ?NeoGenomics? or the ?Company?) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or juri |
|
| February 25, 2021 |
Offer Letter dated May 8, 2020 between Ms. Cynthia J. (Cindy) Dieter and NeoGenomics, Inc. Exhibit 10.15 Exhibit 10.15 /s/ Heather Carter Exhibit 10.15 /s/ Cindy Dieter 05/08/2020 Exhibit 10.15 |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. |
|
| February 25, 2021 |
Employment Agreement dated February 10, 2020 between Mr. Douglas Brown and NeoGenomics, Inc. Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 Exhibit 10.14 /s/ Douglas M. VanOort /s/ Douglas Brown Exhibit 10.14 Exhibit 10.14 |
|
| February 25, 2021 |
Subsidiaries of NeoGenomics, Inc. EXHIBIT 21.1 SUBSIDIARIES OF NEOGENOMICS, INC. NeoGenomics Laboratories, Inc., a Florida corporation NeoGenomics Bioinformatics, Inc., a Florida corporation NeoGenomics Foundation, Inc., a Florida Corporation Genesis Acquisition Holdings Corp., a Delaware corporation Genoptix, Inc., a Delaware corporation Minuet Diagnostics, Inc., a Delaware corporation Cynogen, Inc., a Delaware corporation Clarie |
|
| February 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2021 NEOGENOMICS, INC. |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2021 NEOGENOMICS, INC. |
|
| February 24, 2021 |
NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter Exhibit 99.1 NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter Fourth-Quarter 2020 Results and Highlights: •Consolidated revenue increased 18% to $126 million •Clinical Services revenue increased 14% to $107 million •Pharma Services revenue increased 43% to $19 million •Pharma Services backlog increased 60% to $209 million Ft. Myers, Florida - February 24, 2021 - NeoGeno |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: NeoGenomics Inc. Title of Class of Securities: Common Stock CUSIP Number: 64049M209 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| January 25, 2021 |
us64049m2098012521.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NEOGENOMICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64049M209 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 11, 2021 |
irpresentation01112021 Exhibit 99.1 Our Common Purpose Our Values Our Vision FY 2019 Key Figures Revenue: Revenue Growth: Clinical Test Volume: Gross Margin: Adjusted EBITDA: • • • • • • *Excluding non-core COVID-19 PCR Testing • • • • • • • • • • NOTE: 13 locations across 3 continents Demographics Precision Medicine & Drug Development Upside Potential: Emerging Opportunities 22.2 31% increase by |
